Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
Venuti; Michael C.
Address:
San Francisco, CA
No. of patents:
25
Patents:












Patent Number Title Of Patent Date Issued
6171578 Benzodiazepine derivatives for imaging thrombi January 9, 2001
The invention provides compounds comprising glycoprotein IIb/IIIa receptor-binding benzodiazepine derivatives covalently linked to metal ion chelators. The compounds of the invention may be labeled with a radionuclide such as .sup.99m Tc and used to image thrombi.
5876970 Surfactant compositions and methods March 2, 1999
Stable lung surfactant compositions are provided, as well as methods for their preparation, modification, formulation, assay, and therapeutic use.
5155132 Naphthalene lipoxygenase-inhibiting agents October 13, 1992
Psoriasis in mammals is relieved by topically administering naphthalenes of the formula: ##STR1## wherein: R.sup.1 is lower alkoxy or optionally substituted phenoxy;R.sup.2 is hydrogen, lower alkyl, optionally substituted phenyl or optionally substituted phenylalkyl;R.sup.3 is hydrog
5134161 Method for treating disease states in mammals with naphthalene lipoxygenase-inhibiting agents July 28, 1992
Psoriasis in mammals is relieved by topically administering naphthalenes of the formula: ##STR1## wherein: R.sup.1 is lower alkoxy or optionally substituted phenoxy,R.sup.2 is the same as R.sup.1, or R.sup.2 is hydrogen, lower alkyl, optionally substituted phenyl or optionally substi
5091558 Naphthalene anti-psoriatic agents February 25, 1992
Psoriasis in mammals is relieved by topically administering naphthalenes of the formula: ##STR1## wherein: R.sup.1 is alkoxy, alkylthio, optionally substituted phenoxy or optionally substituted phenylthio;R.sup.2 is hydrogen, lower alkyl, optionally substituted phenyl or optional
5089657 Naphthalene anti-psoriatic agents February 18, 1992
Psoriasis in mammals is relieved by topically administering naphthalenes of the formula: ##STR1## wherein:R.sup.1 is lower alkoxy or optionally substituted phenoxy;R.sup.2 is hydrogen, lower alkyl, optionally substituted phenyl or optionally substituted phenyl-lower-alkyl;R.sup.3 is
4970297 Transglutaminase inhibitors November 13, 1990
This invention is directed to compounds of the formula: ##STR1## or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, wherein:n is 0, 1 or 2;p and q are independently 0, 1 or 2 and the sum of (p+q) is less than or equal to 3;X is selected from the group consis
4946845 Naphthalene anti-psoriatic agents August 7, 1990
Psoriasis in mammals is relieved by topically administering naphthalenes of the formula: ##STR1## wherein: R.sup.1 and R.sup.2 are the same and are lower alkoxy or optionally substituted phenoxy,R.sup.3 is lower alkyl, lower alkoxy, or halo and m is 0, 1 or 2 or R.sup.3 is option
4929630 Transglutaminase inhibitors May 29, 1990
The present invention is directed to certain 3,5 substituted, 4,5-dihydroisoxazoles, and methods for their use. These compounds are transglutaminase inhibitors, and are particularly effective in the inhibition of epidermal transglutaminase and the treatment of acne.
4912120 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibitors March 27, 1990
The present invention is directed to certain 3,5 substituted, 4,5-dihydroisoxazoles, and methods for their use. These compounds are transgulatminase inhibitors, and are particularly effective in the inhibition of epidermal transglutaminase and the treatment of acne.
4840965 Naphthalene anti-psoriatic agents June 20, 1989
Naphthalenes of the formula: ##STR1## wherein: m is 1 or 2;n is 1, 2, or 3;R.sup.1 is alkyl of one to seven carbon atoms or an optionally substituted phenyl;R.sup.2 is hydrogen, lower alkyl, lower alkoxy, optionally substituted phenyl, optionally substituted phenyl-lower-alkyl, optio
4792556 Naphthalene anti-psoriatic agents December 20, 1988
Psoriasis in mammals is relieved by topically administering naphthalenes of the formula: ##STR1## wherein: R.sup.1 and R.sup.2 are the same and are lower alkoxy or optionally substituted phenoxy,R.sup.3 is lower alkyl, lower alkoxy, or halo and m is 0, 1 or 2 or R.sup.3 is option
4786652 Naphthalene anti-psoriatic agents November 22, 1988
Psoriasis in mammals is relieved by topically administering naphthalenes of the formula: ##STR1## wherein: R.sup.1 is lower alkoxy or optionally substituted phenoxy,R.sup.2 is the same as R.sup.1, or R.sup.2 is hydrogen, lower alkyl, optionally substituted phenyl or optionally substi
4761416 N-N-disubstituted-.omega.-[2-amino-3-(carbonylmethyl)-3, 4-dihydroquinazolinyl]oxyalkylamides an August 2, 1988
Pharmaceutical compositions comprising, or compositions consisting essentially of, compounds according to the formula ##STR1## or an optical isomer thereof are disclosed, wherein the substituents A, Z and R.sup.1 are defined herein. The invention is also directed to certain compo
4758587 Naphthalene anti-psoriatic agents July 19, 1988
Psoriasis in mammals is relieved by topically administering naphthalenes of the formula: ##STR1## wherein: R.sup.1 is lower alkoxy or optionally substituted phenoxy;R.sup.2 is hydrogen, lower alkyl, optionally substituted phenyl or optionally substituted phenylalkyl;R.sup.3 is hydrog
4739056 N-N-disubstituted-omega-(2-amino-3-(carbonylmethyl)-3,4-dihy droquinazolinyl)oxy-alkylamides and April 19, 1988
Compounds are disclosed according to the formula ##STR1## or an optical isomer thereof. The compounds of Formula I are cyclic AMP phosphodiesterase inhibitors useful as antithrombotic and inotropic agents and the like in mammals.
4690925 (2-Oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl) oxyalkylamides properties having phosphodi September 1, 1987
Compounds according to the formula ##STR1## , its optical isomers, or a pharmaceutically acceptable salt thereof wherein:m and n are integers of 1 to 6;R.sub.1 is hydrogen or alkyl of 1 to 4 carbons;R.sub.2 is hydrogen or R.sub.1 and R.sub.2 are combined to form an oxo group;R.sub.3
4670434 (2-oxo-3-methylene-1,2,3,5-tetrahydroimidazo[2,1-b]q uinazolinyl)oxyalkylamides useful as cyclic June 2, 1987
This invention relates to compounds of the formula ##STR1## and the pharmaceutically acceptable acid addition salts thereof wherein the various substituents are defined herein. These compounds are cyclic AMP phosphodiesterase inhibitors useful as antithrombotic and inotropic agen
4663320 (2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinoazolinyl)oxyalkylamides, compositions and the use th May 5, 1987
Compounds according to the formula ##STR1## an optical isomer thereof, or a pharmaceutically acceptable acid addition salt thereof wherein:n is an integer of 1 to 6;R.sub.1 is hydrogen or alkyl of 1 to 4 carbons;R.sub.2 is hydrogen or R.sub.1 and R.sub.2 are combined to form an oxo g
4593120 Naphthalene anti-psoriatic agents June 3, 1986
Psoriasis in mammals is relieved by topically administering naphthalenes of the formula: ##STR1## wherein: R.sup.1 and R.sup.2 are the same and are lower alkoxy, lower alkylthio, optionally substituted phenoxy or optionally substituted phenylthio,R.sup.3 is lower alkyl, lower alk
4593029 Novel .omega.-(N-imidazolyl)alkyl ethers of 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones June 3, 1986
Novel compound of the formula ##STR1## wherein n is an integer of 1 to 8;R.sub.1 is hydrogen or alkyl of 1-6 carbons;R.sub.2 is hydrogen;R.sub.3 is hydrogen, alkyl of 1-6 carbons, phenyl, benzyl, hydroxy lower alkyl, carbamoyl alkyl, carboxyalkyl, alkoxycarbonylalkyl;R.sub.4 is hydrogen,
4551459 Method of treating heart failure using (2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolinyl)oxya November 5, 1985
Compounds according to the formula ##STR1## and the pharmaceutically acceptable acid addition salts thereof wherein: n is an integer of 1 to 6;R.sub.1 is hydrogen or alkyl of 1 to 4 carbon;R.sub.2 is hydrogen or R.sub.1 and R.sub.2 combined are oxo;R.sub.3 is hydrogen, alkyl of 1 to 6 ca
4490371 N,N-Di substituted-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl)oxyalkyl amides December 25, 1984
Compounds according to the formula ##STR1## and the pharmaceutically acceptable acid addition salts thereof wherein: n is an integer of 1 to 6;R.sub.1 is hydrogen or alkyl of 1 to 4 carbons;R.sub.2 is hydrogen or R.sub.1 and R.sub.2 are combined to form an oxo group;R.sub.3 is hydrog
4466981 Naphthalene anti-psoriatic agents August 21, 1984
Psoriasis in mammals is relieved by topically administering naphthalenes of the formula: ##STR1## wherein: R.sup.1 and R.sup.2 are lower alkoxy or lower alkylthio;R.sup.3 is hydrogen, lower alkyl, lower alkoxy, optionally substituted phenyl, optionally substituted phenyl lower alkyl,
4296042 Preparation of unsaturated aliphatic insect pheromones using cyclic phosphonium ylids October 20, 1981
This process relates to the synthesis of unsaturated aliphatic esters useful as insect sex attractants, including gossyplure, the insect sex pheromone of the pink bollworm moth, Pectinophora gossypiella, and intermediates therefor. The process utilizes a cyclic phosphonium (Wittig) r










 
 
  Recently Added Patents
Self cleaning rake
5-lipoxygenase-activating protein (FLAP) inhibitors
Representing polarized light in computer models
Cellulose ester compositions having low birefringence and films made therefrom
Buildable dinnerware
Hybrid CMOS nanowire mesh device and PDSOI device
Cable sheath
  Randomly Featured Patents
Method and apparatus for image reading capable of obtaining adequate white reference data for shading correction
Pump, electronic apparatus, and cooling system
Pager receiver capable of avoiding an unpleasing interruption of a displayed message
Cobalt-catalyzed asymmetric cyclopropanation of electron-deficient olefins
Guard beam for automotive door structure
Turn in place mounting
Negative tonable photohardenable element
Label assembly with verifying means and method of making and using
Method for synthesis of aliphatic isocyanates from aromatic isocyanates
Lithographic printing plate precursor